Soluble lutein in combination with brilliant blue as a new dye for chromovitrectomy.
A new dye for vitreoretinal surgery comprised of soluble lutein/zeaxanthin 1 % and brilliant blue 0.025 % is advantageous compared with other dyes currently used for chromovitrectomy, and showed no signs of toxicity at 1 month of follow-up.


OBJECTIVE
To evaluate the feasibility and safety of a dye [soluble lutein/zeaxanthin (LZ) 1 % and brilliant blue (BB) 0.025 %] for improving removal of vitreous, epiretinal membranes (ERM), and internal limiting membranes (ILM) in humans.


METHODS
We prospectively evaluated 18 eyes treated surgically for a macular hole or ERM. Eighteen surgeons performed chromovitrectomy using the dye, and completed a questionnaire to evaluate the efficacy and safety of the dye. . Examinations included best-corrected visual acuity and intraocular pressure measurements and optical coherence tomography, fluorescein angiography, and autofluorescence performed at baseline and days 1, 7, and 30 postoperatively.


RESULTS
The green dye was deposited on the posterior pole; vigorous dye flushing into the vitreous cavity was unnecessary. All surgeons reported that the ILM stained greenish-blue; 94.4 % reported ILM peeling adequate; the ERM stained poorly. No evidence of toxicity was observed.


CONCLUSIONS
The new dye deposited on the posterior pole due to its higher density. The ability to stain the ILM was similar to BB. The new dye has ability to stain the vitreous, hyaloid, and especially the ILM satisfactorily. The new dye may be useful during chromovitrectomy.
Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Emmerson
E
Badaro
Bruno
B
Furlani
Juliana
J
Prazeres
Mauricio
M
Maia
Acácio Alves Souza
AA
Lima
Diogo
D
Souza-Martins
Cristina
C
Muccioli
Luiz Filipe Adami
LF
Lucatto
Rubens
R
Belfort
D000368:Aged; D000369:Aged, 80 and over; D001485:Basement Membrane / Q000473:pathology; D002863:Chromogenic Compounds / Q000009:adverse effects; D004338:Drug Combinations; D058450:Endotamponade; D019773:Epiretinal Membrane / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D005451:Fluorescein Angiography; D005466:Fluorocarbons / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D014975:Lutein / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016684:Prone Position; D011446:Prospective Studies; D012167:Retinal Perforations / Q000175:diagnosis / Q000601:surgery*; D012394:Rosaniline Dyes / Q000009:adverse effects; D011795:Surveys and Questionnaires; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy / Q000379:methods*; D014822:Vitreous Body / Q000473:pathology
D002863:Chromogenic Compounds; D004338:Drug Combinations; D005466:Fluorocarbons; D012394:Rosaniline Dyes; C042852:perflutren; C004692:coomassie Brilliant Blue; D014975:Lutein